MDxHealth SA (MDxHealth) is a company primarily engaged in the development and commercialization of advanced molecular diagnostic solutions for cancer assessment and diagnosis. The company operates in the molecular diagnostics industry, focusing on providing non-invasive tests that help in the early detection and management of cancer, particularly prostate cancer. MDxHealth's key statistics include its reliance on a limited number of tests for revenue generation and its operations in the U.S. and European markets.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company’s R&D activities focuses on enhancing its Confirm mdx and Select mdx for Prostate Cancer tests. It also focuses on identifying and developing new prostate cancer biomarkers. Additionally, the company is developing its technology platform to increase throughput and economic efficiencies in its testing and laboratory operations. MDxHealth SA is continuously exploring and developing new and improved clinically relevant products, approaches, and techniques. The company is also leveraging its proprietary portfolio of genes to build a robust portfolio of biomarkers for diagnostic, prognostic, and predictive molecular assays for urology. In FY2024, the company owned 163 granted or pending patent applications which included 15 issued or allowed US patents, five pending US provisional or non-provisional applications, and eight pending international patent applications filed under the Patent Cooperation Treaty (PCT). The company owned 140 patents granted or allowed in countries other than the United States, including Japan, Canada, Israel, and the major European nations. In FY2024, the company spent US$5.8 million on its R&D activities, which as a percentage of revenue stood at 6.5%, and grew 37.7% YoY.